iconstar paper   Hepatitis C Articles (HCV)  
Back grey arrow rt.gif
 
 
The pharmacological properties of IDX19368, a novel nucleotide prodrug, highlight its potential for use in a low-dose DAA regimen for HCV
 
 
  Reported by Jules Levin
 
Presented at the 19th International Symposium on Hepatitis C Virus and Related Viruses; Venice, Italy; October 5-9, 2012
 
J. P. Bilello, C. B. Dousson, C. Pierra, D. Surleraux, M. La Colla, C. Chapron, I. Serra, N. Golitsina, F. Danehy, M. Camire, B. Hernandez-Santiago, J. F. McCarville, S. Bhadresa, X.R. Pan-Zhou, L. B. Lallos, H. Rashidzadeh, K. Gupta, M. Seifer, R. Rush and D. N. Standring Idenix Pharmaceuticals, Inc., Cambridge, MA, USA and Montpellier, France.

HCV1.gif

HCV2.gif

HCV3.gif

HCV4.gif

HCV5.gif

HCV6.gif

HCV7.gif

HCV8.gif

 
 
 
 
  iconpaperstack View Older Articles   Back to Top   www.natap.org